RA Drug Clazakizumab Gives a Boost to BMS
By Marie Powers
Tuesday, October 29, 2013
The humanized anti-interleukin (IL)-6 monoclonal antibody (MAb) clazakizumab passed muster in its first major study, a dose-ranging Phase IIb in 418 adults with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.